Kronik Periodontitisli, Periodontal Sağlıklı; Sigara İçen/İçmeyen Bireylerde Doku Düzeyinde Vazoaktif İntestinal Peptit(VIP) Seviyelerinin İmmünohistokimyasal Olarak Belirlenmesi

Yıl 2023, Cilt: 2 Sayı: 1, 154 - 162, 05.06.2023

Mustafa Şimşekyılmaz Taner Arabacı Elif Bilici Beyza Nur Şahin

https://doi.org/10.58711/turkishjdentres.vi.1259516

Öz

Amaç: Periodontal durum ve sigara kullanımının vazoaktif intestinal peptit(VIP) seviyelerine etkisini incelemek. Gereç ve Yöntem: Kronik periodontitisli (KP) ve periodontal sağlıklı sigara içen ve içmeyen dört grup oluşturulmuştur. (Sigara kullanımı yok ve periodontal açıdan sağlıklı bireyler:S, Sigara kullanımı var ve periodontal açıdan sağlıklı bireyler:SS, Sigara kullanımı yok ve kronik periodontitisli bireyler:KP, Sigara kullanımı var ve kronik periodontitisli bireyler:KPS). Alınan periodontal dokular immünohistokimyasal olarak boyanmış ve VIP(+) hücrelerin steoroloji yöntemiyle ortalama sayısal yoğunlukları belirlenmiştir.
Bulgular: Bütün gruplar arasında VIP reseptör ortalama sayısal yoğunluk seviyelerinde istatistiksel olarak anlamlı fark bulunmuştur (p<0.05). VIP’te ise S, SS, KP grupları arasında anlamlı fark gözlenirken (p<0.05); KP ve KPS grupları arasında anlamlı fark gözlenmemiştir (p>0.05).
Sonuç: Pro-inflamatuar yolaktaki sitokinleri etkileyen VIP anti-inflamatuar bir nöropeptit olarak çalışmaktadır. Bu proteinde ve reseptöründe, KP ve sigara kullanımı ile periodontal dokulardaki seviyelerinde artış görülmektedir.

Anahtar Kelimeler

vazoaktif intestinal peptit, kronik periodontitis, sigara kullanımı

Destekleyen Kurum

Atatürk Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi

Proje Numarası

2018/6505

Teşekkür

Bu çalışma, Atatürk Üniversitesi Bilimsel Araştırma Projeleri Koordinasyon Birimi tarafından 2018/6505 numaralı proje ile desteklenmiştir.

Immunohistochemical Determination Of Vasoactive Intestinal Peptide(VIP) Levels In Smokers and Non-Smokers Chronic Periodontitis Patients And Periodontal Healthy Individuals

Öz

Background: The main aim of this study to investigate the effect of periodontal status and smoking on vasoactive intestinal peptide(VIP) levels on periodontal tissue. Material and Method: Patients were divided four groups. Groups were named non-smokers and periodontal healthy individuals(H), smokers and periodontal healthy individuals(HS), non-smokers and chronic periodontitis patients(CP), smokers and chronic periodontitis patients(CPS). Collected periodontal tissue were stained immunohistochemically and then the numerical densities of the VIP(+) cells were determined by steorology method. Results: VIP receptor numerical density levels were statistically significant between all groups (p <0.05). A significant difference was observed between H, HS and CP groups at the VIP level (p <0.05). No significant difference was observed between CP and CPS groups (p> 0.05). Conclusion: The VIP acts as an anti-inflammatory neuropeptide that affects the cytokines in the pro-inflammatory
pathway. There is an increase at the level of this protein and its receptor in periodontal tissue when patients has periodontal disease or they are smokers.

Anahtar Kelimeler

vasoactive intestinal peptite, chronic periodontitis, smoking

Proje Numarası

2018/6505

Kaynakça

• 1. Pihlstrom BL, Michalowicz BS, Johnson NW. Periodontal diseases. The lancet. 2005;366(9499):1809-1820.
• 2. Genco RJ, Borgnakke WS. Risk factors for periodontal disease. Periodontol 2000. 2013;62(1):59-94.
• 3. Armitage GC. Periodontal diagnoses and classification of periodontal diseases. Periodontol 2000. 2004;34(1):9-21.
• 4. Papapanou PN, Sanz M, Buduneli N, et al. Periodontitis: Consensus report of workgroup 2 of the 2017 World Workshop on the Classification of Periodontal and Peri-Implant Diseases and Conditions. J Periodontol. 2018;89:S173-S182.
• 5. Armitage GC. Development of a classification system for periodontal diseases and conditions. Ann Periodontol. 1999;4(1):1-6.
• 6. Erdemir OE. Sigara ve periodontal hastalık. Published online 2005.
• 7. Borojevic T. Smoking and periodontal disease. Mater Socio-Medica. 2012;24(4):274.
• 8. Eke PI, Dye BA, Wei L, Thornton-Evans GO, Genco RJ. Prevalence of periodontitis in adults in the United States: 2009 and 2010. J Dent Res. 2012;91(10):914-920.
• 9. Kocher T, Schwahn C, Gesch D, et al. Risk determinants of periodontal disease–an analysis of the Study of Health in Pomerania (SHIP 0). J Clin Periodontol. 2005;32(1):59-67.
• 10. Kinane DF, Chestnutt IG. Smoking and periodontal disease. Crit Rev Oral Biol Med. 2000;11(3):356-365.
• 11. Leite FRM, Nascimento GG, Baake S, Pedersen LD, Scheutz F, López R. Impact of Smoking Cessation on Periodontitis: A Systematic Review and Meta-analysis of Prospective Longitudinal Observational and Interventional Studies. Nicotine Tob Res Off J Soc Res Nicotine Tob. 2019;21(12):1600-1608. doi:10.1093/ntr/nty147
• 12. Eminoğlu Dö, Çanakçı V. Evaluation of Oxidative Status in Patients With Chronic Periodontitis and Additional Tobacco Abuse: A Cross-Sectional Study. Atatürk Üniversitesi Diş Hekim Fakültesi Derg. 30(4):536-544.
• 13. Alkan EA, Dikilitaş A, Alkan Ö, Parlar A. Sigara ve periodontal hastalık ilişkisi. Acta Odontol Turc. 2013;30(1):49-53.
• 14. Pabst MJ, Pabst KM, Collier JA, et al. Inhibition of neutrophil and monocyte defensive functions by nicotine. J Periodontol. 1995;66(12):1047-1055. doi:10.1902/jop.1995.66.12.1047
• 15. Graswinckel JEM, Van Der Velden U, Van Winkelhoff AJ, Hoek FJ, Loos BG. Plasma antibody levels in periodontitis patients and controls. J Clin Periodontol. 2004;31(7):562-568.
• 16. Güntsch A, Erler M, Preshaw PM, Sigusch BW, Klinger G, Glockmann E. Effect of smoking on crevicular polymorphonuclear neutrophil function in periodontally healthy subjects. J Periodontal Res. 2006;41(3):184-188.
• 17. Kanehira T, Shibata K, Kashiwazaki H, Inoue N, Morita M. Comparison of antioxidant enzymes in saliva of elderly smokers and non-smokers. Gerodontology. 2006;23(1):38-42.
• 18. Kraal JH, Kenney EB. The response of polymorphonuclear leukocytes to chemotictic stimulation for smokers and nonsmokers. J Periodontal Res. 1979;14(5):383-389.
• 19. Boström L, Linder LE, Bergström J. Clinical expression of TNF-alpha in smoking-associated periodontal disease. J Clin Periodontol. 1998;25(10):767-773. doi:10.1111/j.1600-051x.1998.tb02368.x
• 20. Victor FC, Gottlieb AB. TNF-alpha and apoptosis: implications for the pathogenesis and treatment of psoriasis. J Drugs Dermatol JDD. 2002;1(3):264-275.
• 21. Delgado M, Ganea D. Vasoactive intestinal peptide: a neuropeptide with pleiotropic immune functions. Amino Acids. 2013;45(1):25-39. doi:10.1007/s00726-011-1184-8
• 22. Pozo D, Delgado M, Martínez M, et al. Immunobiology of vasoactive intestinal peptide (VIP). Immunol Today. 2000;21(1):7-11. doi:10.1016/s0167-5699(99)01525-x
• 23. Abad C, Niewiadomski P, Loh DW, Waschek J. Neurotransmitter and immunomodulatory actions of VIP and PACAP: lessons from knockout mice. Int J Pept Res Ther. 2006;(12):297-310.
• 24. Gomariz RP, Martinez C, Abad C, Leceta J, Delgado M. Immunology of VIP: a review and therapeutical perspectives. Curr Pharm Des. 2001;7(2):89-111. doi:10.2174/1381612013398374
• 25. Korkmaz OT, Tunçel N, Tunçel M, Oncü EM, Sahintürk V, Celik M. Vasoactive intestinal peptide (VIP) treatment of Parkinsonian rats increases thalamic gamma-aminobutyric acid (GABA) levels and alters the release of nerve growth factor (NGF) by mast cells. J Mol Neurosci MN. 2010;41(2):278-287. doi:10.1007/s12031-009-9307-3
• 26. Lundberg P, Lie A, Bjurholm A, et al. Vasoactive intestinal peptide regulates osteoclast activity via specific
• binding sites on both osteoclasts and osteoblasts. Bone. 2000;27(6):803-810. doi:10.1016/s8756-3282(00)00394-x
• 27. Delgado M, Ganea D. Neuroprotective effect of vasoactive intestinal peptide (VIP) in a mouse model of Parkinson’s disease by blocking microglial activation. FASEB J Off Publ Fed Am Soc Exp Biol. 2003;17(8):944-946. doi:10.1096/fj.02-0799fje
• 28. Vacas E, Bajo AM, Schally AV, Sánchez-Chapado M, Prieto JC, Carmena MJ. Antioxidant activity of vasoactive intestinal peptide in HK2 human renal cells. Peptides. 2012;38(2):275-281. doi:10.1016/j.peptides.2012.09.011
• 29. Silness J, Löe H. Periodontal disease in pregnancy II. Correlation between oral hygiene and periodontal condition. Acta Odontol Scand. 1964;22(1):121-135.
• 30. Löe H, Silness J. Periodontal disease in pregnancy I. Prevalence and severity. Acta Odontol Scand. 1963;21(6):533-551.
• 31. Listgarten MA. Periodontal probing: what does it mean? J Clin Periodontol. 1980;7(3):165-176. doi:10.1111/j.1600- 051x.1980.tb01960.x
• 32. Sterio DC. The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc. 1984;134(2):127-136.
• 33. Glaser J, Greene G, Hendricks S. Stereology for Biological Research: With a Focus on Neuroscience. mbf Press; 2007.
• 34. Gundersen HJG, Jensen EB. The efficiency of systematic sampling in stereology and its prediction. J Microsc. 1987;147(3):229-263.
• 35. Howard V, Reid S, Baddeley A, Boyde A. Unbiased estimation of particle density in the tandem scanning reflected light microscope. J Microsc. 1985;138(Pt 2):203- 212. doi:10.1111/j.1365-2818.1985.tb02613.x
• 36. Luthman J, Friskopp J, Dahllöf G, Ahlström U, Sjöström L, Johansson O. Immunohistochemical study of neurochemical markers in gingiva obtained from periodontitisaffected sites. J Periodontal Res. 1989;24(4):267-278. doi:10.1111/j.1600-0765.1989.tb01792.x
• 37. Linden GJ, Mullally BH, Burden DJ, et al. Changes in vasoactive intestinal peptide in gingival crevicular fluid in response to periodontal treatment. J Clin Periodontol. 2002;29(6):484-489. doi:10.1034/j.1600- 051x.2002.290602.x
• 38. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol Baltim Md 1950. 1999;162(3):1707-1716.
• 39. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNgamma synthesis by T cells. J Neuroimmunol. 1999;96(2):167-181. doi:10.1016/s0165-5728(99)00023-5
• 40. Ganea D, Delgado M. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) as modulators of both innate and adaptive immunity. Crit Rev Oral Biol Med Off Publ Am Assoc Oral Biol. 2002;13(3):229-237. doi:10.1177/154411130201300303
• 41. Delgado M, Pozo D, Martinez C, et al. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J Immunol Baltim Md 1950. 1999;162(4):2358-2367.
• 42. Miotto D, Boschetto P, Bononi I, et al. Vasoactive intestinal peptide receptors in the airways of smokers with chronic bronchitis. Eur Respir J. 2004;24(6):958-963. doi:10.1183/ 09031936.04.10031504
• 43. Boström L, Linder LE, Bergström J. Smoking and crevicular fluid levels of IL-6 and TNF-alpha in periodontal disease. J Clin Periodontol. 1999;26(6):352-357. doi:10.1034/j.1600- 051x.1999.260604.x